Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash from Financing Activities (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Cash from Financing Activities for 9 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 526.01% to $1.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.4 million, a 78.13% decrease, with the full-year FY2024 number at $17.8 million, up 12.81% from a year prior.
  • Cash from Financing Activities was $1.9 million for Q3 2025 at Rein Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $55.6 million in Q1 2021 to a low of -$446000.0 in Q3 2024.
  • A 4-year average of $8.8 million and a median of $738000.0 in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 99.99% in 2024, then soared 526.01% in 2025.
  • Rein Therapeutics' Cash from Financing Activities stood at $1000.0 in 2021, then soared by 1579300.0% to $15.8 million in 2023, then crashed by 99.99% to $1000.0 in 2024, then soared by 189900.0% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Cash from Financing Activities are $1.9 million (Q3 2025), $4.7 million (Q2 2025), and $738000.0 (Q1 2025).